Explore
Trendline
Gilead Sciences Achieves New All-Time Highs Driven by Strong HIV and Liver Disease Portfolio Growth
Gilead Sciences Achieves New All-Time Highs Driven by Strong HIV and Liver Disease Portfolio Growth
Read More
Trendline
Gilead Sciences Advances Biopharmaceutical Portfolio with Focus on HIV, Hepatitis, and Cancer Treatments
Gilead Sciences Advances Biopharmaceutical Portfolio with Focus on HIV, Hepatitis, and Cancer Treatments
Read More
Trendline
Bristol Myers Squibb Advances Neuroscience and Oncology Pipeline with New Late-Stage Projects
Bristol Myers Squibb Advances Neuroscience and Oncology Pipeline with New Late-Stage Projects
Read More
Trendline
Regeneron Pharmaceuticals Defies Skeptics with Strong Performance and Clinical Milestones
Regeneron Pharmaceuticals Defies Skeptics with Strong Performance and Clinical Milestones
Read More
Trendline
Summit Therapeutics to Host Corporate Update and Operational Progress Call on November 30, 2026
Summit Therapeutics to Host Corporate Update and Operational Progress Call on November 30, 2026
Read More
Trendline
Moderna Raises 2026 Revenue Growth Outlook Amidst Personalized Cancer Vaccine Program Success and New Flu Vaccine Approval
Moderna Raises 2026 Revenue Growth Outlook Amidst Personalized Cancer Vaccine Program Success and New Flu Vaccine Approval
Read More
Trendline
Merck's Dividend Growth Outpaces Clorox Despite Lower Current Yield
Merck's Dividend Growth Outpaces Clorox Despite Lower Current Yield
Read More
Trendline
Pfizer Secures Exclusive Licensing Deal with Starna Therapeutics for Autoimmune Disease RNA Medicines
Pfizer Secures Exclusive Licensing Deal with Starna Therapeutics for Autoimmune Disease RNA Medicines
Read More
Trendline
Gilead Sciences' HIV Franchise Drives Revenue Amidst Dividend Growth and Future Medicare Price Negotiations
Gilead Sciences' HIV Franchise Drives Revenue Amidst Dividend Growth and Future Medicare Price Negotiations
Read More
Trendline
Pfizer's New Drug Revenue Surges 32% in Q3 2026 Amidst Patent Cliff Concerns
Pfizer's New Drug Revenue Surges 32% in Q3 2026 Amidst Patent Cliff Concerns
Read More
Trendline
Novartis Projects 5% Sales Growth Through 2031, Boosted by Key Brand Performance
Novartis Projects 5% Sales Growth Through 2031, Boosted by Key Brand Performance
Read More
Trendline
Brookings Institution Proposes Refined Biotech Innovation Support, Questions Current Medicare Exemption Approach
Brookings Institution Proposes Refined Biotech Innovation Support, Questions Current Medicare Exemption Approach
Read More